WESM

Sydney Lupkin

Copyright 2022 NPR. To see more, visit https://www.npr.org.

Two highly anticipated COVID-19 pills have been authorized for emergency use and allocated for shipment to states, but the supply is tight, and the rollout varies from state to state.

Moncef Slaoui, the former head of the Trump administration's Operation Warp Speed, says he's "cautiously optimistic" about how well existing vaccines will hold up against omicron, the latest coronavirus variant of concern.

Omicron has more mutations than previous variants, with around 30 mutations on just its spike protein.

That's worrying for virologists, who note that the spike protein is what vaccines use to "teach" our bodies to recognize the coronavirus.

Sudeep Taksali thought his battle to avoid a medication's steep price tag was over. He was wrong.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Pages